Benefits
Hair Growth Promotion (Mostly Animal Evidence)
Multiple animal studies (Datta 2009, Roy 2008) show methanol or petroleum ether extracts of Eclipta alba applied topically promote telogen-to-anagen transition in mice and reduce hair growth initiation time vs. minoxidil controls in albino rats. Human RCT-level evidence is limited — most claims rest on traditional use plus rodent data.
Hepatoprotective Activity
Eclipta alba is traditionally used in India for liver disorders. Animal studies show hepatoprotection against carbon tetrachloride and other hepatotoxins. A small number of human studies suggest possible benefit in viral hepatitis support, but evidence quality is low and not sufficient to recommend therapeutic use.
Possible Anti-Inflammatory Effects
Wedelolactone (the principal coumestan in Eclipta alba) shows anti-inflammatory activity in vitro via NF-κB inhibition and reduced cytokine production. Clinical translation has not been established in human trials.
Possible 5α-Reductase Inhibition
A 2023 in vitro study suggested Eclipta alba extract may inhibit 5α-reductase — the enzyme finasteride targets in male pattern baldness. This provides a plausible mechanism for traditional hair loss claims, though human clinical confirmation is absent.
Antimicrobial Properties
Eclipta alba shows in vitro antibacterial and antifungal activity, which has been cited as relevant for dandruff (sometimes caused by Malassezia species). Clinical evidence specifically for dandruff or scalp conditions is limited.
Mechanism of action
Hair Cycle Modulation
Eclipta alba extracts induce expression of FGF-7 (KGF) and Sonic hedgehog (Shh) in animal models — both are growth factors that promote anagen-phase entry of hair follicles. They also reduce BMP4 expression, which keeps follicles in telogen (resting) phase. This mechanism explains the observed hair growth promotion in rodent models.
Wedelolactone Bioactivity
Wedelolactone, a coumestan unique to Eclipta and Wedelia genera, is the most-studied bioactive. It inhibits NF-κB, IκB kinase, topoisomerase II, and protein-tyrosine phosphatase 1B. These activities underlie its anti-inflammatory, hepatoprotective, and snake-venom-neutralizing properties documented in preclinical studies.
Antioxidant Activity
Eclipta alba's phenolic constituents (luteolin, apigenin) contribute direct antioxidant activity and induce endogenous antioxidant enzymes via Nrf2 activation. This may underlie hepatoprotective and skin-protective effects.
5α-Reductase Inhibition (Preliminary)
Preliminary in vitro evidence suggests Eclipta alba extract inhibits 5α-reductase, which converts testosterone to dihydrotestosterone (DHT). DHT drives androgenic alopecia. This mechanism — if confirmed in humans — would parallel finasteride's action.
Microcirculation Enhancement
Topical Eclipta alba is reported to enhance scalp microcirculation, increasing nutrient delivery to hair follicles. This is largely a traditional/empirical observation; controlled vasodilatory studies are limited.
Clinical trials
Preclinical study using pigmented C57/BL6 mice in telogen phase. Topical methanol extract of whole-plant Eclipta alba applied to evaluate hair growth promotion. Immunohistochemistry assessed FGF-7, Shh, and BMP4 markers. (Datta, Singh, Singh, Kumar 2009, J Ethnopharmacol)
C57/BL6 mice in telogen hair growth phase. Animal model only — no human data.
Methanol extract showed dose-dependent hair growth promotion. Treated animals showed positive FGF-7 and Shh staining (anagen markers) and reduced BMP4 (telogen marker). Authors conclude potential as a hair growth promoter, with mechanism mediated through hair cycle regulatory factors.
Preclinical study evaluating petroleum ether and ethanol extracts of E. alba in oleaginous cream applied to shaved albino rat skin. 2% minoxidil solution served as positive control. Time to hair growth initiation and completion measured. (Roy, Thakur, Dixit 2008, Arch Dermatol Res)
Albino rats. Animal model only — no human data.
Hair growth initiation time was significantly REDUCED to half vs. control with E. alba extract. Time to complete hair growth cycle also significantly reduced. Effects were comparable to or better than 2% minoxidil — though direct human translation of these results is uncertain.
Comprehensive review of traditional uses, phytochemistry, pharmacology, and toxicity of Eclipta prostrata (synonymous with E. alba). Searched Google Scholar, Web of Science, PubMed, Scifinder, and CNKI through February 2019 with no time limit on included studies. (Feng, Zhai, Xu, Yao, Cao, Cheng, Bao, Zhang 2019, J Ethnopharmacol)
Comprehensive literature review across multiple databases.
Confirms Eclipta prostrata's traditional applications in hair loss, hepatic disorders, hemorrhagic conditions, and skin diseases across Asian and South American medicine. Pharmacological activity reviewed includes hepatoprotection, antimicrobial, anti-inflammatory, and hair growth promotion. Authors note significant phytochemistry/pharmacology progress but limited rigorous human clinical evidence — a recurrent theme in Eclipta research.
About this ingredient
Eclipta alba (synonyms: Eclipta prostrata, 'False Daisy,' Bhringraj) is an annual herb in the Asteraceae family, native to India and tropical regions worldwide. In Ayurveda, it is traditionally regarded as the 'King of Hair' for its purported hair growth and pigmentation effects, applied as oil (Bhringraj oil) or used internally. The principal bioactives are wedelolactone (a coumestan unique to Eclipta and Wedelia), ecliptine, luteolin, apigenin, flavonoids, and various triterpenes.
EVIDENCE: Hair growth claims rest primarily on rodent studies (Datta 2009, Roy 2008) showing topical extracts promote anagen-phase entry and reduce hair growth initiation time comparable to minoxidil. Human RCT-level evidence is sparse — most clinical studies use Eclipta in combined Ayurvedic formulations, complicating attribution. Hepatoprotective claims rest mostly on animal models and traditional use.
SAFETY: Topical use is generally well-tolerated. Oral use is less well-characterized; long-term safety is not established. Pregnancy/lactation data is insufficient.
NOT a substitute for evidence-based hair loss treatment (minoxidil, finasteride for male pattern baldness) in clinically significant alopecia — discuss with a dermatologist.